SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-145698
Filing Date
2022-05-10
Accepted
2022-05-10 07:37:03
Documents
13
Period of Report
2022-05-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d345234d8k.htm   iXBRL 8-K 25954
2 EX-99.1 d345234dex991.htm EX-99.1 88616
  Complete submission text file 0001193125-22-145698.txt   248917

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA itci-20220510.xsd EX-101.SCH 2902
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE itci-20220510_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE itci-20220510_pre.xml EX-101.PRE 10843
7 EXTRACTED XBRL INSTANCE DOCUMENT d345234d8k_htm.xml XML 3208
Mailing Address 430 EAST 29TH STREET NEW YORK NY 10016
Business Address 430 EAST 29TH STREET NEW YORK NY 10016 212-923-3344
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

IRS No.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36274 | Film No.: 22907386
SIC: 2834 Pharmaceutical Preparations